New therapeutic approaches for the treatment of hypertriglyceridemia View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-04-22

AUTHORS

Ioanna Gouni-Berthold, Jonas Schwarz

ABSTRACT

Patients with hypertriglyceridemia (> 150 mg/dl) have an increased risk for atherosclerotic cardiovascular disease, and those with severe hypertriglyceridemia (> 880 mg/dl) also for pancreatitis. The currently available medications to decrease triglyceride levels, such as fibrates, statins, and omega‑3 fatty acids, are in many cases not able to achieve normal triglyceride levels. Therefore, new drugs are in development to address this unmet need. Recently, icosapent ethyl, a purified formulation of the omega-3-fatty acid eicosapentaenoic acid, was approved in Germany for the reduction of cardiovascular events in patients with hypertriglyceridemia and established cardiovascular disease or with diabetes and other risk factors on top of statins. Other new drugs in development are the more selective peroxisome proliferator-activated receptor α (PPARα) modulator, pemafibrate, already approved for the treatment of hypertriglyceridemia in Japan, and inhibitors of ApoC-III and angiopoietin-like 3 (ANGPTL3) in the form of antisense oligonucleotides or siRNAs or fully human monoclonal binding antibodies. Apolipoprotein C-III and ANGPTL3 protein seem to be quite promising targets based on solid genetic data. Larger studies of long duration, many of them currently ongoing, are needed to establish the role these medications will play in the treatment of hypertriglyceridemia in clinical practice. More... »

PAGES

220-227

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00059-022-05113-x

DOI

http://dx.doi.org/10.1007/s00059-022-05113-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1147317491

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35451595


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiopoietin-Like Protein 3", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiopoietin-like Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apolipoprotein C-III", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertriglyceridemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triglycerides", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Str.\u00a062, 50937, K\u00f6ln, Germany", 
          "id": "http://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Str.\u00a062, 50937, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gouni-Berthold", 
        "givenName": "Ioanna", 
        "id": "sg:person.01341766537.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01341766537.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Str.\u00a062, 50937, K\u00f6ln, Germany", 
          "id": "http://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Str.\u00a062, 50937, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwarz", 
        "givenName": "Jonas", 
        "id": "sg:person.012166327420.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012166327420.59"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40265-021-01516-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1138150105", 
          "https://doi.org/10.1007/s40265-021-01516-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11883-021-00914-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1136301265", 
          "https://doi.org/10.1007/s11883-021-00914-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11883-021-00919-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1136818048", 
          "https://doi.org/10.1007/s11883-021-00919-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11883-020-00897-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1134291419", 
          "https://doi.org/10.1007/s11883-020-00897-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12933-021-01291-w", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1137733674", 
          "https://doi.org/10.1186/s12933-021-01291-w"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-04-22", 
    "datePublishedReg": "2022-04-22", 
    "description": "Patients with hypertriglyceridemia (>\u202f150\u202fmg/dl) have an increased risk for atherosclerotic cardiovascular disease, and those with severe hypertriglyceridemia (>\u202f880\u202fmg/dl) also for pancreatitis. The currently available medications to decrease triglyceride levels, such as fibrates, statins, and omega\u20113 fatty acids, are in many cases not able to achieve normal triglyceride levels. Therefore, new drugs are in development to address this unmet need. Recently, icosapent ethyl, a\u00a0purified formulation of the omega-3-fatty acid eicosapentaenoic acid, was approved in Germany for the reduction of cardiovascular events in patients with hypertriglyceridemia and established cardiovascular disease or with diabetes and other risk factors on top of statins. Other new drugs in development are the more selective peroxisome proliferator-activated receptor\u00a0\u03b1 (PPAR\u03b1) modulator, pemafibrate, already approved for the treatment of hypertriglyceridemia in Japan, and inhibitors of ApoC-III and angiopoietin-like\u00a03 (ANGPTL3) in the form of antisense oligonucleotides or siRNAs or fully human monoclonal binding antibodies. Apolipoprotein\u00a0C-III and ANGPTL3\u00a0protein seem to be quite promising targets based on solid genetic data. Larger studies of long duration, many of them currently ongoing, are needed to establish the role these medications will play in the treatment of hypertriglyceridemia in clinical practice.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00059-022-05113-x", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1087175", 
        "issn": [
          "0340-9937", 
          "1615-6692"
        ], 
        "name": "Herz", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "47"
      }
    ], 
    "keywords": [
      "treatment of hypertriglyceridemia", 
      "triglyceride levels", 
      "cardiovascular disease", 
      "selective peroxisome proliferator-activated receptor", 
      "peroxisome proliferator-activated receptor", 
      "top of statins", 
      "new drugs", 
      "atherosclerotic cardiovascular disease", 
      "normal triglyceride levels", 
      "proliferator-activated receptor", 
      "new therapeutic approaches", 
      "cardiovascular events", 
      "icosapent ethyl", 
      "available medications", 
      "risk factors", 
      "severe hypertriglyceridemia", 
      "binding antibodies", 
      "therapeutic approaches", 
      "hypertriglyceridemia", 
      "clinical practice", 
      "unmet need", 
      "apoC-III", 
      "larger study", 
      "eicosapentaenoic acid", 
      "promising target", 
      "longer duration", 
      "medications", 
      "statins", 
      "patients", 
      "treatment", 
      "disease", 
      "drugs", 
      "fatty acids", 
      "fibrates", 
      "pancreatitis", 
      "pemafibrate", 
      "diabetes", 
      "ANGPTL3", 
      "antibodies", 
      "apolipoproteins", 
      "receptors", 
      "levels", 
      "risk", 
      "inhibitors", 
      "duration", 
      "acid", 
      "siRNAs", 
      "antisense", 
      "modulator", 
      "target", 
      "factors", 
      "cases", 
      "development", 
      "protein", 
      "study", 
      "role", 
      "events", 
      "reduction", 
      "genetic data", 
      "need", 
      "practice", 
      "data", 
      "Japan", 
      "form", 
      "Germany", 
      "approach", 
      "formulation", 
      "ethyl", 
      "top"
    ], 
    "name": "New therapeutic approaches for the treatment of hypertriglyceridemia", 
    "pagination": "220-227", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147317491"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00059-022-05113-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35451595"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00059-022-05113-x", 
      "https://app.dimensions.ai/details/publication/pub.1147317491"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_945.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00059-022-05113-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05113-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05113-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05113-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05113-x'


 

This table displays all metadata directly associated to this object as RDF triples.

189 TRIPLES      21 PREDICATES      107 URIs      94 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00059-022-05113-x schema:about N273d8b10b79f4ac0a70ea6eb26323da7
2 N2c21ea1e7db542a5a54a42e7fc6d14fc
3 N33a7254f61f24247896a4c5a461d6440
4 N4154780a142f4e7189b23ef9a6f2b522
5 N4568c7cbeef34df991c85d113dd6d17d
6 N5310e70675954310865f2d3216088cd4
7 N8d45eb7104e34da8923a91023845e05f
8 Nae4187a42d03471fa282a2b28f7831a5
9 anzsrc-for:11
10 anzsrc-for:1115
11 schema:author N842756a61dcd49d381d682e6b66dbc6b
12 schema:citation sg:pub.10.1007/s11883-020-00897-x
13 sg:pub.10.1007/s11883-021-00914-7
14 sg:pub.10.1007/s11883-021-00919-2
15 sg:pub.10.1007/s40265-021-01516-y
16 sg:pub.10.1186/s12933-021-01291-w
17 schema:datePublished 2022-04-22
18 schema:datePublishedReg 2022-04-22
19 schema:description Patients with hypertriglyceridemia (> 150 mg/dl) have an increased risk for atherosclerotic cardiovascular disease, and those with severe hypertriglyceridemia (> 880 mg/dl) also for pancreatitis. The currently available medications to decrease triglyceride levels, such as fibrates, statins, and omega‑3 fatty acids, are in many cases not able to achieve normal triglyceride levels. Therefore, new drugs are in development to address this unmet need. Recently, icosapent ethyl, a purified formulation of the omega-3-fatty acid eicosapentaenoic acid, was approved in Germany for the reduction of cardiovascular events in patients with hypertriglyceridemia and established cardiovascular disease or with diabetes and other risk factors on top of statins. Other new drugs in development are the more selective peroxisome proliferator-activated receptor α (PPARα) modulator, pemafibrate, already approved for the treatment of hypertriglyceridemia in Japan, and inhibitors of ApoC-III and angiopoietin-like 3 (ANGPTL3) in the form of antisense oligonucleotides or siRNAs or fully human monoclonal binding antibodies. Apolipoprotein C-III and ANGPTL3 protein seem to be quite promising targets based on solid genetic data. Larger studies of long duration, many of them currently ongoing, are needed to establish the role these medications will play in the treatment of hypertriglyceridemia in clinical practice.
20 schema:genre article
21 schema:isAccessibleForFree false
22 schema:isPartOf Nb689be6cb095422b82823ba0db806157
23 Nbcd78d60e75e4a31b7d76e601b762fea
24 sg:journal.1087175
25 schema:keywords ANGPTL3
26 Germany
27 Japan
28 acid
29 antibodies
30 antisense
31 apoC-III
32 apolipoproteins
33 approach
34 atherosclerotic cardiovascular disease
35 available medications
36 binding antibodies
37 cardiovascular disease
38 cardiovascular events
39 cases
40 clinical practice
41 data
42 development
43 diabetes
44 disease
45 drugs
46 duration
47 eicosapentaenoic acid
48 ethyl
49 events
50 factors
51 fatty acids
52 fibrates
53 form
54 formulation
55 genetic data
56 hypertriglyceridemia
57 icosapent ethyl
58 inhibitors
59 larger study
60 levels
61 longer duration
62 medications
63 modulator
64 need
65 new drugs
66 new therapeutic approaches
67 normal triglyceride levels
68 pancreatitis
69 patients
70 pemafibrate
71 peroxisome proliferator-activated receptor
72 practice
73 proliferator-activated receptor
74 promising target
75 protein
76 receptors
77 reduction
78 risk
79 risk factors
80 role
81 selective peroxisome proliferator-activated receptor
82 severe hypertriglyceridemia
83 siRNAs
84 statins
85 study
86 target
87 therapeutic approaches
88 top
89 top of statins
90 treatment
91 treatment of hypertriglyceridemia
92 triglyceride levels
93 unmet need
94 schema:name New therapeutic approaches for the treatment of hypertriglyceridemia
95 schema:pagination 220-227
96 schema:productId N46fc125fac3c4a43abb7d73b8042c374
97 Nad910c5066aa4cfe897fba7bf563db78
98 Nae08d807e4d54628b725a58979af0dab
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147317491
100 https://doi.org/10.1007/s00059-022-05113-x
101 schema:sdDatePublished 2022-09-02T16:08
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher Nb36f7b8e0ae243d8bdefe2762c3bb117
104 schema:url https://doi.org/10.1007/s00059-022-05113-x
105 sgo:license sg:explorer/license/
106 sgo:sdDataset articles
107 rdf:type schema:ScholarlyArticle
108 N273d8b10b79f4ac0a70ea6eb26323da7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Cardiovascular Diseases
110 rdf:type schema:DefinedTerm
111 N2c21ea1e7db542a5a54a42e7fc6d14fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Hydroxymethylglutaryl-CoA Reductase Inhibitors
113 rdf:type schema:DefinedTerm
114 N33a7254f61f24247896a4c5a461d6440 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Triglycerides
116 rdf:type schema:DefinedTerm
117 N39fb3450e6164569823a22f889628171 rdf:first sg:person.012166327420.59
118 rdf:rest rdf:nil
119 N4154780a142f4e7189b23ef9a6f2b522 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Apolipoprotein C-III
121 rdf:type schema:DefinedTerm
122 N4568c7cbeef34df991c85d113dd6d17d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Humans
124 rdf:type schema:DefinedTerm
125 N46fc125fac3c4a43abb7d73b8042c374 schema:name pubmed_id
126 schema:value 35451595
127 rdf:type schema:PropertyValue
128 N5310e70675954310865f2d3216088cd4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Hypertriglyceridemia
130 rdf:type schema:DefinedTerm
131 N842756a61dcd49d381d682e6b66dbc6b rdf:first sg:person.01341766537.07
132 rdf:rest N39fb3450e6164569823a22f889628171
133 N8d45eb7104e34da8923a91023845e05f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Angiopoietin-like Proteins
135 rdf:type schema:DefinedTerm
136 Nad910c5066aa4cfe897fba7bf563db78 schema:name dimensions_id
137 schema:value pub.1147317491
138 rdf:type schema:PropertyValue
139 Nae08d807e4d54628b725a58979af0dab schema:name doi
140 schema:value 10.1007/s00059-022-05113-x
141 rdf:type schema:PropertyValue
142 Nae4187a42d03471fa282a2b28f7831a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Angiopoietin-Like Protein 3
144 rdf:type schema:DefinedTerm
145 Nb36f7b8e0ae243d8bdefe2762c3bb117 schema:name Springer Nature - SN SciGraph project
146 rdf:type schema:Organization
147 Nb689be6cb095422b82823ba0db806157 schema:issueNumber 3
148 rdf:type schema:PublicationIssue
149 Nbcd78d60e75e4a31b7d76e601b762fea schema:volumeNumber 47
150 rdf:type schema:PublicationVolume
151 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
152 schema:name Medical and Health Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
155 schema:name Pharmacology and Pharmaceutical Sciences
156 rdf:type schema:DefinedTerm
157 sg:journal.1087175 schema:issn 0340-9937
158 1615-6692
159 schema:name Herz
160 schema:publisher Springer Nature
161 rdf:type schema:Periodical
162 sg:person.012166327420.59 schema:affiliation grid-institutes:grid.6190.e
163 schema:familyName Schwarz
164 schema:givenName Jonas
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012166327420.59
166 rdf:type schema:Person
167 sg:person.01341766537.07 schema:affiliation grid-institutes:grid.6190.e
168 schema:familyName Gouni-Berthold
169 schema:givenName Ioanna
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01341766537.07
171 rdf:type schema:Person
172 sg:pub.10.1007/s11883-020-00897-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1134291419
173 https://doi.org/10.1007/s11883-020-00897-x
174 rdf:type schema:CreativeWork
175 sg:pub.10.1007/s11883-021-00914-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1136301265
176 https://doi.org/10.1007/s11883-021-00914-7
177 rdf:type schema:CreativeWork
178 sg:pub.10.1007/s11883-021-00919-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1136818048
179 https://doi.org/10.1007/s11883-021-00919-2
180 rdf:type schema:CreativeWork
181 sg:pub.10.1007/s40265-021-01516-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1138150105
182 https://doi.org/10.1007/s40265-021-01516-y
183 rdf:type schema:CreativeWork
184 sg:pub.10.1186/s12933-021-01291-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1137733674
185 https://doi.org/10.1186/s12933-021-01291-w
186 rdf:type schema:CreativeWork
187 grid-institutes:grid.6190.e schema:alternateName Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Str. 62, 50937, Köln, Germany
188 schema:name Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Str. 62, 50937, Köln, Germany
189 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...